+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Immunotherapy Market 2023-2027

  • PDF Icon

    Report

  • 168 Pages
  • August 2023
  • Region: Global
  • TechNavio
  • ID: 5514976
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The cancer immunotherapy market is forecasted to grow by USD 38.57 bn during 2022-2027, accelerating at a CAGR of 7.42% during the forecast period. The report on the cancer immunotherapy market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high prevalence of cancer, growing awareness among consumers regarding cancer immunotherapy, and strong R and D pipeline of monoclonal antibodies.

The cancer immunotherapy market is segmented as below:

By Type

  • Monoclonal antibodies
  • Check point inhibitors and immunomodulators
  • Cancer vaccines

By Application

  • Lung cancer
  • Breast cancer
  • Colorectal cancer
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • Rest of World (ROW)
This study identifies the adoption of various strategies for cancer immunotherapy market growth as one of the prime reasons driving the cancer immunotherapy market growth during the next few years. Also, emerging novel therapies for treating cancer and availability of advanced diagnostic modalities will lead to sizable demand in the market.

The report on the cancer immunotherapy market covers the following areas:

  • Cancer immunotherapy market sizing
  • Cancer immunotherapy market forecast
  • Cancer immunotherapy market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading cancer immunotherapy market vendors that include Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Dendreon Pharmaceuticals LLC, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Immunocore Holdings Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., and Takeda Pharmaceutical Co. Ltd.. Also, the cancer immunotherapy market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1 Executive Summary
1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market By Geographical Landscape
Exhibit 05: Executive Summary - Chart on Market Segmentation by Type
Exhibit 06: Executive Summary - Chart on Market Segmentation by Application
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
2 Market Landscape
2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics
3 Market Sizing
3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
4.1 Global cancer immunotherapy market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on global cancer immunotherapy market 2017 - 2021 ($ billion)
4.2 Type Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
4.3 Application Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Application Segment 2017 - 2021 ($ billion)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
5 Five Forces Analysis
5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Type
6.1 Market segments
Exhibit 30: Chart on Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Type - Market share 2022-2027 (%)
6.2 Comparison by Type
Exhibit 32: Chart on Comparison by Type
Exhibit 33: Data Table on Comparison by Type
6.3 Monoclonal antibodies - Market size and forecast 2022-2027
Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
6.4 Check point inhibitors and immunomodulators - Market size and forecast 2022-2027
Exhibit 38: Chart on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
Exhibit 39: Data Table on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
Exhibit 40: Chart on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)
6.5 Cancer vaccines - Market size and forecast 2022-2027
Exhibit 42: Chart on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
Exhibit 43: Data Table on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
Exhibit 44: Chart on Cancer vaccines - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Cancer vaccines - Year-over-year growth 2022-2027 (%)
6.6 Market opportunity by Type
Exhibit 46: Market opportunity by Type ($ billion)
Exhibit 47: Data Table on Market opportunity by Type ($ billion)
7 Market Segmentation by Application
7.1 Market segments
Exhibit 48: Chart on Application - Market share 2022-2027 (%)
Exhibit 49: Data Table on Application - Market share 2022-2027 (%)
7.2 Comparison by Application
Exhibit 50: Chart on Comparison by Application
Exhibit 51: Data Table on Comparison by Application
7.3 Lung cancer - Market size and forecast 2022-2027
Exhibit 52: Chart on Lung cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 53: Data Table on Lung cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 54: Chart on Lung cancer - Year-over-year growth 2022-2027 (%)
Exhibit 55: Data Table on Lung cancer - Year-over-year growth 2022-2027 (%)
7.4 Breast cancer - Market size and forecast 2022-2027
Exhibit 56: Chart on Breast cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 57: Data Table on Breast cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 58: Chart on Breast cancer - Year-over-year growth 2022-2027 (%)
Exhibit 59: Data Table on Breast cancer - Year-over-year growth 2022-2027 (%)
7.5 Colorectal cancer - Market size and forecast 2022-2027
Exhibit 60: Chart on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 61: Data Table on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
Exhibit 62: Chart on Colorectal cancer - Year-over-year growth 2022-2027 (%)
Exhibit 63: Data Table on Colorectal cancer - Year-over-year growth 2022-2027 (%)
7.6 Others - Market size and forecast 2022-2027
Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Application
Exhibit 68: Market opportunity by Application ($ billion)
Exhibit 69: Data Table on Market opportunity by Application ($ billion)
8 Customer Landscape
8.1 Customer landscape overview
Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
9.1 Geographic segmentation
Exhibit 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibit 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
9.2 Geographic comparison
Exhibit 73: Chart on Geographic comparison
Exhibit 74: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Germany - Market size and forecast 2022-2027
Exhibit 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibit 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.9 China - Market size and forecast 2022-2027
Exhibit 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibit 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 102: Data Table on China - Year-over-year growth 2022-2027 (%)
9.10 France - Market size and forecast 2022-2027
Exhibit 103: Chart on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 104: Data Table on France - Market size and forecast 2022-2027 ($ billion)
Exhibit 105: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibit 106: Data Table on France - Year-over-year growth 2022-2027 (%)
9.11 Canada - Market size and forecast 2022-2027
Exhibit 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibit 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity By Geographical Landscape
Exhibit 111: Market opportunity By Geographical Landscape ($ billion)
Exhibit 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
10 Drivers, Challenges, and Trends
10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 113: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends
11 Vendor Landscape
11.1 Overview
11.2 Vendor landscape
Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 115: Overview on factors of disruption
11.4 Industry risks
Exhibit 116: Impact of key risks on business
12 Vendor Analysis
12.1 Vendors covered
Exhibit 117: Vendors covered
12.2 Market positioning of vendors
Exhibit 118: Matrix on vendor position and classification
12.3 Amgen Inc.
Exhibit 119: Amgen Inc. - Overview
Exhibit 120: Amgen Inc. - Product/Service
Exhibit 121: Amgen Inc. - Key offerings
12.4 AstraZeneca Plc
Exhibit 122: AstraZeneca Plc - Overview
Exhibit 123: AstraZeneca Plc - Product/Service
Exhibit 124: AstraZeneca Plc - Key news
Exhibit 125: AstraZeneca Plc - Key offerings
12.5 Bayer AG
Exhibit 126: Bayer AG - Overview
Exhibit 127: Bayer AG - Business segments
Exhibit 128: Bayer AG - Key news
Exhibit 129: Bayer AG - Key offerings
Exhibit 130: Bayer AG - Segment focus
12.6 Bristol Myers Squibb Co.
Exhibit 131: Bristol Myers Squibb Co. - Overview
Exhibit 132: Bristol Myers Squibb Co. - Product/Service
Exhibit 133: Bristol Myers Squibb Co. - Key news
Exhibit 134: Bristol Myers Squibb Co. - Key offerings
12.7 Eli Lilly and Co.
Exhibit 135: Eli Lilly and Co. - Overview
Exhibit 136: Eli Lilly and Co. - Product/Service
Exhibit 137: Eli Lilly and Co. - Key news
Exhibit 138: Eli Lilly and Co. - Key offerings
12.8 F. Hoffmann La Roche Ltd.
Exhibit 139: F. Hoffmann La Roche Ltd. - Overview
Exhibit 140: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 141: F. Hoffmann La Roche Ltd. - Key news
Exhibit 142: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 143: F. Hoffmann La Roche Ltd. - Segment focus
12.9 Gilead Sciences Inc.
Exhibit 144: Gilead Sciences Inc. - Overview
Exhibit 145: Gilead Sciences Inc. - Product/Service
Exhibit 146: Gilead Sciences Inc. - Key news
Exhibit 147: Gilead Sciences Inc. - Key offerings
12.10 GlaxoSmithKline Plc
Exhibit 148: GlaxoSmithKline Plc - Overview
Exhibit 149: GlaxoSmithKline Plc - Business segments
Exhibit 150: GlaxoSmithKline Plc - Key news
Exhibit 151: GlaxoSmithKline Plc - Key offerings
Exhibit 152: GlaxoSmithKline Plc - Segment focus
12.11 Immunocore Holdings Plc
Exhibit 153: Immunocore Holdings Plc - Overview
Exhibit 154: Immunocore Holdings Plc - Product/Service
Exhibit 155: Immunocore Holdings Plc - Key offerings
12.12 Johnson and Johnson
Exhibit 156: Johnson and Johnson - Overview
Exhibit 157: Johnson and Johnson - Business segments
Exhibit 158: Johnson and Johnson - Key news
Exhibit 159: Johnson and Johnson - Key offerings
Exhibit 160: Johnson and Johnson - Segment focus
12.13 Merck KGaA
Exhibit 161: Merck KGaA - Overview
Exhibit 162: Merck KGaA - Business segments
Exhibit 163: Merck KGaA - Key news
Exhibit 164: Merck KGaA - Key offerings
Exhibit 165: Merck KGaA - Segment focus
12.14 Novartis AG
Exhibit 166: Novartis AG - Overview
Exhibit 167: Novartis AG - Business segments
Exhibit 168: Novartis AG - Key offerings
Exhibit 169: Novartis AG - Segment focus
12.15 Pfizer Inc.
Exhibit 170: Pfizer Inc. - Overview
Exhibit 171: Pfizer Inc. - Product/Service
Exhibit 172: Pfizer Inc. - Key news
Exhibit 173: Pfizer Inc. - Key offerings
12.16 Sanofi
Exhibit 174: Sanofi - Overview
Exhibit 175: Sanofi - Business segments
Exhibit 176: Sanofi - Key news
Exhibit 177: Sanofi - Key offerings
Exhibit 178: Sanofi - Segment focus
12.17 Takeda Pharmaceutical Co. Ltd.
Exhibit 179: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 180: Takeda Pharmaceutical Co. Ltd. - Product/Service
Exhibit 181: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 182: Takeda Pharmaceutical Co. Ltd. - Key offerings
13 Appendix
13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 183: Inclusions checklist
Exhibit 184: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 185: Currency conversion rates for US$
13.4 Research methodology
Exhibit 186: Research methodology
Exhibit 187: Validation techniques employed for market sizing
Exhibit 188: Information sources
13.5 List of abbreviations
Exhibit 189: List of abbreviations
List of Exhibits
Exhibits 1: Executive Summary - Chart on Market Overview
Exhibits 2: Executive Summary - Data Table on Market Overview
Exhibits 3: Executive Summary - Chart on Global Market Characteristics
Exhibits 4: Executive Summary - Chart on Market By Geographical Landscape
Exhibits 5: Executive Summary - Chart on Market Segmentation by Type
Exhibits 6: Executive Summary - Chart on Market Segmentation by Application
Exhibits 7: Executive Summary - Chart on Incremental Growth
Exhibits 8: Executive Summary - Data Table on Incremental Growth
Exhibits 9: Executive Summary - Chart on Vendor Market Positioning
Exhibits 10: Parent market
Exhibits 11: Market Characteristics
Exhibits 12: Offerings of vendors included in the market definition
Exhibits 13: Market segments
Exhibits 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
Exhibits 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
Exhibits 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits 18: Historic Market Size - Data Table on global cancer immunotherapy market 2017 - 2021 ($ billion)
Exhibits 19: Historic Market Size - Type Segment 2017 - 2021 ($ billion)
Exhibits 20: Historic Market Size - Application Segment 2017 - 2021 ($ billion)
Exhibits 21: Historic Market Size - Geography Segment 2017 - 2021 ($ billion)
Exhibits 22: Historic Market Size - Country Segment 2017 - 2021 ($ billion)
Exhibits 23: Five forces analysis - Comparison between 2022 and 2027
Exhibits 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits 26: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits 27: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits 28: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits 29: Chart on Market condition - Five forces 2022 and 2027
Exhibits 30: Chart on Type - Market share 2022-2027 (%)
Exhibits 31: Data Table on Type - Market share 2022-2027 (%)
Exhibits 32: Chart on Comparison by Type
Exhibits 33: Data Table on Comparison by Type
Exhibits 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
Exhibits 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
Exhibits 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibits 38: Chart on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
Exhibits 39: Data Table on Check point inhibitors and immunomodulators - Market size and forecast 2022-2027 ($ billion)
Exhibits 40: Chart on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)
Exhibits 41: Data Table on Check point inhibitors and immunomodulators - Year-over-year growth 2022-2027 (%)
Exhibits 42: Chart on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
Exhibits 43: Data Table on Cancer vaccines - Market size and forecast 2022-2027 ($ billion)
Exhibits 44: Chart on Cancer vaccines - Year-over-year growth 2022-2027 (%)
Exhibits 45: Data Table on Cancer vaccines - Year-over-year growth 2022-2027 (%)
Exhibits 46: Market opportunity by Type ($ billion)
Exhibits 47: Data Table on Market opportunity by Type ($ billion)
Exhibits 48: Chart on Application - Market share 2022-2027 (%)
Exhibits 49: Data Table on Application - Market share 2022-2027 (%)
Exhibits 50: Chart on Comparison by Application
Exhibits 51: Data Table on Comparison by Application
Exhibits 52: Chart on Lung cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 53: Data Table on Lung cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 54: Chart on Lung cancer - Year-over-year growth 2022-2027 (%)
Exhibits 55: Data Table on Lung cancer - Year-over-year growth 2022-2027 (%)
Exhibits 56: Chart on Breast cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 57: Data Table on Breast cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 58: Chart on Breast cancer - Year-over-year growth 2022-2027 (%)
Exhibits 59: Data Table on Breast cancer - Year-over-year growth 2022-2027 (%)
Exhibits 60: Chart on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 61: Data Table on Colorectal cancer - Market size and forecast 2022-2027 ($ billion)
Exhibits 62: Chart on Colorectal cancer - Year-over-year growth 2022-2027 (%)
Exhibits 63: Data Table on Colorectal cancer - Year-over-year growth 2022-2027 (%)
Exhibits 64: Chart on Others - Market size and forecast 2022-2027 ($ billion)
Exhibits 65: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
Exhibits 66: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibits 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
Exhibits 68: Market opportunity by Application ($ billion)
Exhibits 69: Data Table on Market opportunity by Application ($ billion)
Exhibits 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits 71: Chart on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 72: Data Table on Market share By Geographical Landscape 2022-2027 (%)
Exhibits 73: Chart on Geographic comparison
Exhibits 74: Data Table on Geographic comparison
Exhibits 75: Chart on North America - Market size and forecast 2022-2027 ($ billion)
Exhibits 76: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
Exhibits 77: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibits 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
Exhibits 79: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibits 80: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
Exhibits 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
Exhibits 83: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibits 84: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
Exhibits 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
Exhibits 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibits 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
Exhibits 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibits 91: Chart on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 92: Data Table on US - Market size and forecast 2022-2027 ($ billion)
Exhibits 93: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibits 94: Data Table on US - Year-over-year growth 2022-2027 (%)
Exhibits 95: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibits 96: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
Exhibits 97: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 98: Data Table on Germany - Year-over-year growth 2022-2027 (%)
Exhibits 99: Chart on China - Market size and forecast 2022-2027 ($ billion)
Exhibits 100: Data Table on China - Market size and forecast 2022-2027 ($ billion)
Exhibits 101: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibits 102: Data Table on China - Year-over-year growth 2022-2027 (%)
Exhibits 103: Chart on France - Market size and forecast 2022-2027 ($ billion)
Exhibits 104: Data Table on France - Market size and forecast 2022-2027 ($ billion)
Exhibits 105: Chart on France - Year-over-year growth 2022-2027 (%)
Exhibits 106: Data Table on France - Year-over-year growth 2022-2027 (%)
Exhibits 107: Chart on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibits 108: Data Table on Canada - Market size and forecast 2022-2027 ($ billion)
Exhibits 109: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 110: Data Table on Canada - Year-over-year growth 2022-2027 (%)
Exhibits 111: Market opportunity By Geographical Landscape ($ billion)
Exhibits 112: Data Tables on Market opportunity By Geographical Landscape ($ billion)
Exhibits 113: Impact of drivers and challenges in 2022 and 2027
Exhibits 114: Overview on Criticality of inputs and Factors of differentiation
Exhibits 115: Overview on factors of disruption
Exhibits 116: Impact of key risks on business
Exhibits 117: Vendors covered
Exhibits 118: Matrix on vendor position and classification
Exhibits 119: Amgen Inc. - Overview
Exhibits 120: Amgen Inc. - Product/Service
Exhibits 121: Amgen Inc. - Key offerings
Exhibits 122: AstraZeneca Plc - Overview
Exhibits 123: AstraZeneca Plc - Product/Service
Exhibits 124: AstraZeneca Plc - Key news
Exhibits 125: AstraZeneca Plc - Key offerings
Exhibits 126: Bayer AG - Overview
Exhibits 127: Bayer AG - Business segments
Exhibits 128: Bayer AG - Key news
Exhibits 129: Bayer AG - Key offerings
Exhibits 130: Bayer AG - Segment focus
Exhibits 131: Bristol Myers Squibb Co. - Overview
Exhibits 132: Bristol Myers Squibb Co. - Product/Service
Exhibits 133: Bristol Myers Squibb Co. - Key news
Exhibits 134: Bristol Myers Squibb Co. - Key offerings
Exhibits 135: Eli Lilly and Co. - Overview
Exhibits 136: Eli Lilly and Co. - Product/Service
Exhibits 137: Eli Lilly and Co. - Key news
Exhibits 138: Eli Lilly and Co. - Key offerings
Exhibits 139: F. Hoffmann La Roche Ltd. - Overview
Exhibits 140: F. Hoffmann La Roche Ltd. - Business segments
Exhibits 141: F. Hoffmann La Roche Ltd. - Key news
Exhibits 142: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits 143: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits 144: Gilead Sciences Inc. - Overview
Exhibits 145: Gilead Sciences Inc. - Product/Service
Exhibits 146: Gilead Sciences Inc. - Key news
Exhibits 147: Gilead Sciences Inc. - Key offerings
Exhibits 148: GlaxoSmithKline Plc - Overview
Exhibits 149: GlaxoSmithKline Plc - Business segments
Exhibits 150: GlaxoSmithKline Plc - Key news
Exhibits 151: GlaxoSmithKline Plc - Key offerings
Exhibits 152: GlaxoSmithKline Plc - Segment focus
Exhibits 153: Immunocore Holdings Plc - Overview
Exhibits 154: Immunocore Holdings Plc - Product/Service
Exhibits 155: Immunocore Holdings Plc - Key offerings
Exhibits 156: Johnson and Johnson - Overview
Exhibits 157: Johnson and Johnson - Business segments
Exhibits 158: Johnson and Johnson - Key news
Exhibits 159: Johnson and Johnson - Key offerings
Exhibits 160: Johnson and Johnson - Segment focus
Exhibits 161: Merck KGaA - Overview
Exhibits 162: Merck KGaA - Business segments
Exhibits 163: Merck KGaA - Key news
Exhibits 164: Merck KGaA - Key offerings
Exhibits 165: Merck KGaA - Segment focus
Exhibits 166: Novartis AG - Overview
Exhibits 167: Novartis AG - Business segments
Exhibits 168: Novartis AG - Key offerings
Exhibits 169: Novartis AG - Segment focus
Exhibits 170: Pfizer Inc. - Overview
Exhibits 171: Pfizer Inc. - Product/Service
Exhibits 172: Pfizer Inc. - Key news
Exhibits 173: Pfizer Inc. - Key offerings
Exhibits 174: Sanofi - Overview
Exhibits 175: Sanofi - Business segments
Exhibits 176: Sanofi - Key news
Exhibits 177: Sanofi - Key offerings
Exhibits 178: Sanofi - Segment focus
Exhibits 179: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibits 180: Takeda Pharmaceutical Co. Ltd. - Product/Service
Exhibits 181: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibits 182: Takeda Pharmaceutical Co. Ltd. - Key offerings
Exhibits 183: Inclusions checklist
Exhibits 184: Exclusions checklist
Exhibits 185: Currency conversion rates for US$
Exhibits 186: Research methodology
Exhibits 187: Validation techniques employed for market sizing
Exhibits 188: Information sources
Exhibits 189: List of abbreviations

Executive Summary

The publisher recognizes the following companies as the key players in the global cancer immunotherapy market: Amgen Inc., Amneal Pharmaceuticals Inc., AstraZeneca Plc, Bayer AG, Bristol Myers Squibb Co., Dendreon Pharmaceuticals LLC, Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gilead Sciences Inc., GlaxoSmithKline Plc, Immunocore Holdings Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck KGaA, Novartis AG, Pfizer Inc., Sanofi, Seagen Inc., and Takeda Pharmaceutical Co. Ltd..

Commenting on the report, an analyst from the research team said: 'The latest trend gaining momentum in the market is adoption of various strategies for cancer immunotherapy market growth.'

According to the report, one of the major drivers for this market is the high prevalence of cancer.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc.
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Bristol Myers Squibb Co.
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Fresenius SE and Co. KGaA
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Immunocore Holdings Plc
  • Inovio Pharmaceuticals Inc.
  • Johnson and Johnson
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Seagen Inc.
  • Takeda Pharmaceutical Co. Ltd.

Related Topics

Related Reports

Cancer Immunotherapy - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Cancer Immunotherapy - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 100 Pages
  • Global
From
Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027 - Product Image

Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer including Executive and Consultant Guides. 2023 to 2027

  • Report
  • 256 Pages
  • Global
From
America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

America Cancer Immunotherapy - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 110 Pages
  • Global
From
Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032 - Product Image

Cancer Immunotherapy Market Report by Therapy Type, Application, End User, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics),Regional Outlook- Global Forecast up to 2030 - Product Image

Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics),Regional Outlook- Global Forecast up to 2030

  • Report
  • 116 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.